Study Reports Improved Tolerability with Biomimetic Exosome Retinal

A novel retinal formulation delivered via a biomimetic exosome platform was associated with significant clinical improvements in photodamaged skin without reported irritation, according to a 12-week study published in the Journal of Cosmetic Dermatology.

In the single-center study (HRET-1224), 20 women aged 35 to 65 years with mild-to-moderate photodamage applied a nightly retinal product (RetaXome Daily Retinal Hydrator, HYDRINITY Accelerated Skin Science). Investigators evaluated erythema, skin tone, texture, and fine lines and wrinkles at baseline and at follow-up visits through week 12.

Mean erythema decreased by 68% from baseline at week 12, with statistically significant reductions observed at each follow-up visit (P values were not reported in the press materials). Skin tone showed visible improvement by week 2, with a 56% overall improvement at week 12. Skin texture improved progressively throughout the study, with a 63% improvement from baseline at week 12. Fine lines and wrinkles were reduced by 36% at week 12, with statistically significant improvements at all follow-up visits.

No product-related adverse events were reported during the study period. Participant-reported outcomes indicated that 95% of participants were satisfied and would recommend the product.

"Retinal has long been recognized as one of the most effective ingredients for photoaged skin but tolerability has remained its greatest limitation," said Michael Gold, MD, FAAD, lead investigator and board-certified dermatologist. "What's remarkable about this study is that we achieved the hallmark benefits of retinal—improved tone, smoother texture, reduced wrinkles—without the typical dryness, flaking, or irritation. The biomimetic exosome delivery system fundamentally changes the way we approach retinoid therapy."